Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0Clinical and Translational Radiation Oncology

Management of late urinary side effects after pelvic radiation therapy: a scoping review

  1. 1Applied Radiation Therapy Trinity (ARTT), Discipline of Radiation Therapy, School of Medicine, Trinity St. James's Cancer Institute, Trinity College Dublin, University of Dublin, Dublin, Ireland

Abstract

Background: Radiation therapy (RT) is a cornerstone treatment for pelvic malignancies but can cause durable urinary side effects that impair quality of life. Presentations range from haematuria and irritative symptoms to stricture, fistula, osteomyelitis, and end-stage urinary failure. This scoping review maps the management strategies for late urinary side effects after pelvic RT.

Methods: A PRISMA-ScR-guided search of PubMed and Embase identified studies published from January 2015 to April 2026. Primary studies reporting management outcomes were included. Two reviewers assessed full-text eligibility. Data were charted by syndrome, intervention, design, population, RT characteristics, follow-up and outcomes. Risk of bias in randomised trials was assessed using RoB.

Results: 69 studies of previously irradiated patients were included, predominantly retrospective cohorts. RT modality was reported in 56% of publications, total dose in 33%, and the interval from RT to toxicity in 70%. Hyperbaric oxygen therapy (HBOT) had the strongest evidence for radiation cystitis, supported by randomised data and long-term follow-up. Reconstructive surgery for urethral and ureteral strictures achieved acceptable patency, but recurrence and incontinence remained common. Fistula, osteomyelitis, and refractory bleeding were often managed with salvage diversion in severe or refractory cases, which reduced pain and treatment burden despite substantial perioperative morbidity.

Conclusions: Evidence is strongest for HBOT in chronic radiation cystitis. Elsewhere, management rests on retrospective, expert-centre series. Clinical decision-making is best guided by syndrome, severity, and tissue quality, treating prior RT modality and dose as markers of injury burden, with timely referral and shared decision-making when repeated intervention fails to provide durable control.

Related

  1. Urinary Complications and Injuries Related to Vaginal Mesh Surgery for Pelvic Organ Prolapse: Prevention and Management
    Aleksandra Piątek, Gabriela Kołodyńska, Krystian Kaczmarek +3
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Current State of Adjuvant Hormone Therapy in Prostate Cancer and in the Management of Pelvic Nodal Recurrence: A Narrative Review
    Barbara D’Andrea, Antonietta Montagna, Ilaria Benevento +13
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textGeneral medicineCrossrefEurope PMC
  3. Self‐Management Interventions for Lower Urinary Tract Symptoms After Radical Prostatectomy: A Scoping Review of Intervention Components, Outcomes and Research Gaps
    Koji Amano, Kumi Suzuki
    Nursing OpenPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  4. Renal Abscess Secondary to Urinary Tract Obstruction Caused by Pelvic Organ Prolapse: A Report of Two Cases
    Hiroki Sai, Kumiko Kato, Atsushi Kiyota +2
    IJU case reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Interventional strategies for inferior phrenic artery management in yttrium‑90 selective internal radiation therapy for hepatocellular carcinoma: A single‑center retrospective study
    Yong Liao, Xin Huang, Ziwei Liang +13
    European Journal of Nuclear Medicine and Molecular ImagingPeer-reviewedCC BY-NC-ND 4.0Full textMedical imaging & radiologyPMC
BibTeX
@article{mullaney2026management,
  title = {{Management of late urinary side effects after pelvic radiation therapy: a scoping review}},
  author = {Laura Mullaney and Salma Bennani},
  journal = {Clinical and Translational Radiation Oncology},
  year = {2026},
  month = oct,
  doi = {10.1016/j.ctro.2026.101332},
  url = {https://doi.org/10.1016/j.ctro.2026.101332},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Management of late urinary side effects after pelvic radiation therapy: a scoping review
AU  - Laura Mullaney
AU  - Salma Bennani
PY  - 2026
DA  - 2026/10/21
JO  - Clinical and Translational Radiation Oncology
DO  - 10.1016/j.ctro.2026.101332
UR  - https://doi.org/10.1016/j.ctro.2026.101332
AB  - Background: Radiation therapy (RT) is a cornerstone treatment for pelvic malignancies but can cause durable urinary side effects that impair quality of life. Presentations range from haematuria and irritative symptoms to stricture, fistula, osteomyelitis, and end-stage urinary failure. This scoping review maps the management strategies for late urinary side effects after pelvic RT.  Methods: A PRISMA-ScR-guided search of PubMed and Embase identified studies published from January 2015 to April 2026. Primary studies reporting management outcomes were included. Two reviewers assessed full-text eligibility. Data were charted by syndrome, intervention, design, population, RT characteristics, follow-up and outcomes. Risk of bias in randomised trials was assessed using RoB.  Results: 69 studies of previously irradiated patients were included, predominantly retrospective cohorts. RT modality was reported in 56% of publications, total dose in 33%, and the interval from RT to toxicity in 70%. Hyperbaric oxygen therapy (HBOT) had the strongest evidence for radiation cystitis, supported by randomised data and long-term follow-up. Reconstructive surgery for urethral and ureteral strictures achieved acceptable patency, but recurrence and incontinence remained common. Fistula, osteomyelitis, and refractory bleeding were often managed with salvage diversion in severe or refractory cases, which reduced pain and treatment burden despite substantial perioperative morbidity.  Conclusions: Evidence is strongest for HBOT in chronic radiation cystitis. Elsewhere, management rests on retrospective, expert-centre series. Clinical decision-making is best guided by syndrome, severity, and tissue quality, treating prior RT modality and dose as markers of injury burden, with timely referral and shared decision-making when repeated intervention fails to provide durable control.
SN  - 2405-6308
ER  -